Effect of zoledronate on the clinical efficacy and IL-8, IL-10 and osteocalcin levels in perimenopausal with osteoporosis
10.3969/j.issn.1005-1678.2016.12.024
- VernacularTitle:唑来膦酸钠对围绝经期综合征伴骨质疏松患者的临床疗效及IL-8、IL-10、骨钙素水平的影响
- Author:
Jian FANG
;
Songyi JIANG
;
Ying ZHENG
- Keywords:
perimenopausal syndrome;
osteoporosis;
zoledronate;
osteocalcin
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(12):87-90
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of zoledronate on the clinical efficacy and IL-8, IL-10 and osteocalcin levels in perimenopausal women with osteoporosis.Methods A total of 72 cases menopausal syndrome with osteoporosis from January 2014 to March 2015 in Hangzhou Third People's Hospital of Yuhang District were randomly divided into two groups with 36 cases in each group.Patients in the control group were treated with routine oral administration of calcium carbonate D3 and alpha D3, and the observation group was treated with zoledronate acid sodium on this basis for four weeks.Serum inflammatory factor and bone metabolism index were measured before and after treatment , VAS score and bone mineral density were measured, and the clinical effect was compared.Results Compared with before treatment, two groups of serum ALP, BGP levels and VAS score were significantly decreased (P<0.05), IL-8 and TNF-αlevels decreased (P<0.05), IL-10 level increased (P<0.05), lumbar(L1 ~4), bilateral hip and femoral neck BMD increased (P<0.05); compared with the control group, serum ALP, BGP levels and VAS score in the observation group was lower (P<0.05), IL-8, TNF-αlevels were lower (P<0.05), IL-10 level was higher (P<0.05), lumbar(L1 ~4), bilateral hip and femoral neck BMD were higher (P<0.05), the treatment effective rate was higher (P <0.05).Conclusion Zoledronate in the treatment of perimenopausal syndrome with osteoporosis is significant clinical efficacy, it can effectively relieve the inflammatory symptoms and bone and joint pain, inhibit bone reduction.
